tbuckley/cabot-search huggingface dataset:
1784TiP Pasireotide as maintenance treatment in SSTR2/3/5-expressing synovial sarcoma and desmoplastic small round cell tumor: The PAMSARC study
Authors: R.F. Schlenk, C. Heining, E. Gnutzmann, S.S.L. Roldan, L. Heiligenthal, M. Sparber Sauer, D.A. Hahn, U. Dirksen, R.W. Hamacher, A. Floercken, A. Thorwarth, C. Deinzer, V. Gaidzik, C.M. van Tilburg, D. Hübschmann, K. Arndt, S.M. Pfister, H. Glimm, S. Fröhling, C.E. Heilig
Journal: Annals of Oncology (2024)
1743P A phase II study of fruquintinib in the 1L or 2L treatment of unresectable metastatic soft tissue sarcoma
Authors: Z. Luo, X. Zhang, T. Zhao, B. Zheng, W. Yan, Y. Chen, Y. Xu, C. Wang, J. Zhang, J. Wang, L. Yu, X. Liu
Journal: Annals of Oncology (2024)
1766P Updated results of the RINGSIDE phase II trial and open-label extension of AL102 for treatment of desmoid tumors
Authors: B. Kasper, M. Gounder, R. Chugh, A. Singh, B.A. Van Tine, V. Andelkovic, E. Choy, J. Lewin, R. Ratan, J. Yovell, R.L. Jones
Journal: Annals of Oncology (2024)
1790P Phase II data of lurbinectedin (LUR) and irinotecan (IRI) in relapsed small cell lung cancer (SCLC) patients (pts) with chemotherapy-free interval (CTFI)&gt;30 days (d)
Authors: J. Zugazagoitia, A. Falcon Gonzalez, A.F. Navarro Mendivil, A. Sanchez Gastaldo, P.F. Simoes da Rocha, G.M. Cote, B. Bockorny, J. Molina Cerrillo, A. Artal, J. Baena Espinar, A. Gil Torralvo, S. Ponce Aix, H. Bote De Cabo, J. Martinez Perez, S. Martínez, J.A. López-Vilariño, C. Kahatt, J. Gómez, L.G. Paz-Ares
Journal: Annals of Oncology (2024)
1752P A retrospective single-center study of outcomes to immune checkpoint blockade-based therapy in leiomyosarcoma
Authors: O. Babatunde, E. Rosenbaum, C.M. Kelly, R. Desir-Camille, M.L. Keohan, L. Banks, V. Avutu, J. Chan, D. Reed, M. Gounder, R.G. Maki, P. Chi, M. Dickson, W.D. Tap, S.P. D'Angelo, S. Movva
Journal: Annals of Oncology (2024)
1792P Molecular characterization from IMfirst: Atezolizumab plus chemotherapy in extensive-stage small cell lung cancer (ES-SCLC) in Spain
Authors: M. Cobo Dols, M. Dómine Gómez, J. de Castro Carpeño, A.L. Moreno Vega, S. Ponce Aix, E. Arriola Aperribay, E. Carcereny, M. Majem, G. Huidobro Vence, E. Esteban González, J. Fuentes Pradera, A.L.O. Ortega Granados, M. Guillot Morales, B. Massuti Sureda, P. Lianes Barragán, N. González Mancha, C.A. Fajardo, L. García Palacios, N. Lerones Laborda, M.R. García Campelo
Journal: Annals of Oncology (2024)
1757P Proceedings of the think tank for osteosarcoma medical advisory board meeting
Authors: S.P. Chawla, B.A. Van Tine, N. Federman, J. Schwab, R.L. Jones, V. Subbiah, W. Swaney, N.S. Chawla, T. Spencer, N. Afshar, W. Hoos, N. Feldman, E.M. Gordon
Journal: Annals of Oncology (2024)
1763P Initial tumour size and residual mitotic count post-neoadjuvant imatinib linked to shorter relapse-free survival in GIST patients
Authors: J. Pozas Perez, A. Wall, L. Mavroeidis, K. Sun, K. Thway, D. Lindsay, M.J. Smith, C. Benson, R.L. Jones, A. Napolitano
Journal: Annals of Oncology (2024)
1789P Second OS interim analysis from BEAT-SC: A randomized phase III study of bevacizumab (bev) or placebo in combination with atezolizumab and platinum-based chemotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC)
Authors: B. Han, Y. Ohe, M. Nishio, S. Watanabe, X. Ren, S. Murakami, N. Yang, I. Okamoto, G. Li, N. Katakami, X. Liu, N. Hamaguchi, Y. Nakagawa, M. Hayashi, T. Nanki, C. Qian, N. Yamamoto
Journal: Annals of Oncology (2024)
VSTM2A reverses immunosuppression in colorectal cancer through antagonizing PD-L1/PD-1 interaction
Authors: Yujuan Dong, Jiaxun Jade Liu, Yunfei Zhou, Wei Kang, Shanglin Li, Alvin Hk Cheung, Hu Yi, Rui Liao, Nathalie Wong, Chi Chun Wong, Simon Ng, Jun Yu
Journal: Molecular Therapy (2024)
Recurrent Pulmonary Veno-Occlusive Disease after Lung Transplantation
Authors: Esther J Nossent, Gregorius D. Nossent, Lilian J. Meijboom, Erik A. M. Verschuuren, Chistiaan T. Gan, Jurjan Aman, Harm Jan Bogaard, Teodora Radonic, Peter Dorfmüller, Anton Vonk Noordegraaf
Journal: American Journal of Respiratory and Critical Care Medicine (2024)
1765P Second-line targeted therapy patterns and outcomes of advanced gastrointestinal stromal tumor: A prospective, multicentered real-world study
Authors: X. Zhang, H. Sun, A. Chen, H. Wang, X. Wu, M. Liu, L. Wang, X. Feng, Z. Li, T. Chen, Y. Yin, X. Wu, J. Zhang, Y. Liu, L. Fan, K. Sun, Y. Xia
Journal: Annals of Oncology (2024)
1783P Genetic predisposition in adult sarcoma patients: Beyond TP53
Authors: O. Rohr, A. Jouinot, A. Chansavang, A. Srikaran, F. Goldwasser, P. Boudou Rouquette, S. De Percin, G. Beinse, J. Noel, A. Toussaint, N. Hamzaoui, E. Pasmant, C. Tlemsani
Journal: Annals of Oncology (2024)
1762P Utility of circulating tumor DNA (ctDNA) as a molecular biomarker in the phase II trial of imatinib plus binimetinib in patients with treatment-naïve, advanced gastrointestinal stromal tumor (GIST)
Authors: C.M. Kelly, M. Bradic, S. Saunds, V. Avutu, J. Chan, S.P. D'Angelo, M. Dickson, M. Gounder, M.L. Keohan, S. Movva, E. Rosenbaum, E.K. Bartlett, A. Crago, V. Strong, S. Singer, C. Antonescu, M. Berger, L-X. Qin, W.D. Tap, P. Chi
Journal: Annals of Oncology (2024)
1753P Outcomes of multidisciplinary treatment of localized myxofibrosarcoma: Retrospective analysis from a reference center
Authors: I.A. Kalinowska, P. Teterycz, J. Skoczylas, M. Zdzienicki, M. Wagrodzki, P. Rutkowski, H. Kosela-Paterczyk
Journal: Annals of Oncology (2024)
1777P Molecular profiling from next-generation sequencing (NGS) reveals new potential therapeutic targets in patients with pediatric-type sarcomas
Authors: A.P. Conley, A. Aukhadieva, I. Zhuk, M. Voropaeva, A. Novokreshchenova, A.E. Shevkoplias, K. Zirov, A. Makarova, A. Dubrovskaya, A. Nadiryan, L. Balabanian, A. Bagaev, E. Choy, R. Ratan, L. Bednyagin, S.P. Chawla
Journal: Annals of Oncology (2024)
1786O BMS-986012 (anti-fucosyl-monosialoganglioside-1 [fuc-GM1]) with carboplatin + etoposide + nivolumab (CE/NIVO) as first-line (1L) therapy in extensive-stage small cell lung cancer (ES-SCLC): Interim analysis (IA) of a randomized phase II study
Authors: E. Kalinka, I. Bahce, A.F. Navarro Mendivil, N. Ready, Q.S-C. Chu, S. Sugawara, A. Sibille, M. Provencio Pulla, M.L. Johnson, J.T.J.N. Hiltermann, T-E. Ciuleanu, R. Dziadziuszko, A. Santo, Y. Zhang, Y. Liu, R. Sarmiento, S. Tannenbaum-Dvir, L. Ojalvo, J. Wu, K.J. O'Byrne
Journal: Annals of Oncology (2024)
1791P Thoracic radiotherapy plus maintenance durvalumab after first-line carboplatin and etoposide plus durvalumab in extensive-stage disease small cell lung cancer (ED-SCLC): A multicenter single-arm open-label phase II trial (SAKK 15/19)tle
Authors: A. Addeo, None D. Dietrich, N. Mach, M.T. Mark, M. Joerger, P.R. Froesch, L. Wannesson De Nicola, D. König, E. Fernandez, A. Patzen, H. Vees, C. Picardi, M. Frueh
Journal: Annals of Oncology (2024)
1788P Final overall survival analysis of JCOG1205/1206: Phase III study of irinotecan/cisplatin (IP) versus etoposide/cisplatin (EP) for completely resected high-grade neuroendocrine carcinoma (HGNEC) of the lung
Authors: S. Niho, H. Kenmotsu, M. Tsuboi, M. Wakabayashi, G. Ishii, H. Asahina, K. Watanabe, M. Kiyoshima, T. Iwata, Y. Nakamura, K. Naoki, T. Yoshikawa, K. Nishino, W. Nishio, T. Yokoyama, N. Mitome, H. Asamura, Y. Ohe, S-I. Watanabe
Journal: Annals of Oncology (2024)
1787P Intracranial response in patients (pts) with baseline (BL) brain metastases (BM) and extensive-stage (ES) small cell lung cancer (SCLC) treated with ifinatamab deruxtecan (I-DXd) in the IDeate-Lung01 study
Authors: M.L. Johnson, P.F. Simoes da Rocha, Y.J. Kim, Y. Chen, L.G. Paz-Ares, N. Girard, C.L. Hann, M. Nishio, M-J. Ahn, M. Qian, M. Tang, J. Godard, J. Singh, C.M. Rudin
Journal: Annals of Oncology (2024)
1774P Immunological-molecular profiling of chondrosarcoma (ChS)
Authors: P. Rutkowski, A.E. Zając, A. Szumera-Cieckiewicz, J. Piatkowski, P. Teterycz, E. Palmerini, A. Dutour, J. Tuziak, M. Wagrodzki, A. Tysarowski, M. Gambarotti, G. Frega, M. Pierini, A. Righi, G. Magagnoli, M. Jean-Denis, T. Ibrahim, J-Y. Blay, P. Golik, A.M. Czarnecka
Journal: Annals of Oncology (2024)
1769P Safety and efficacy with vimseltinib in patients (pts) with tenosynovial giant cell tumor (TGCT) who received no prior anti–colony-stimulating factor 1 (CSF1) therapy: Ongoing phase II study
Authors: C. Serrano, J-Y. Blay, P. Rutkowski, H. Gelderblom, S. Stacchiotti, A. Falcon Gonzalez, J. Desai, A. Le Cesne, V. Ferraresi, E. Palmerini, B.A. Wilky, A.J. Wagner, N.M. Bernthal, M. van de Sande, S. Narasimhan, B. Harrow, M.G. Sharma, R. Ruiz-Soto, M.L. Sherman, W.D. Tap
Journal: Annals of Oncology (2024)
1773P Genomic and transcriptomic analysis of chondrosarcomas to explore new potential treatment options
Authors: K. Zirov, M. Voropaeva, A. Aukhadieva, A. Makarova, A.E. Shevkoplias, A. Novokreshchenova, A. Dubrovskaya, D. Lebedev, S.T. Yong, J.H. Brown, S.P. Chawla, G.M. Cote, J.A. Livingston, V. Subbiah, D. Araujo, A. Bagaev, L. Bednyagin, A.P. Conley
Journal: Annals of Oncology (2024)
1749P Vertebral MRI in the screening for bone metastasis in myxoid liposarcoma: Is it justified?
Authors: T. Moussa, T.S. Assi, I. Kasraoui, B. Verret, C. Henon, R. Bahleda, A. Le Cesne, C. Balleyguier
Journal: Annals of Oncology (2024)
1751P Clinical and survival data of 336 myxoid liposarcoma patients: The Gustave Roussy experience
Authors: T.S. Assi, T. Moussa, C. Ngo, B. Verret, C. Henon, R. Bahleda, M. Faron, C. Honoré, A. Levy, C. Le Pechoux, A. Le Cesne
Journal: Annals of Oncology (2024)
1760P Impact of adjuvant imatinib on recurrence for neurofibromatosis type 1 (NF1) associated GISTs: An analysis of the RECKGIST cohort from the French NETSARC+ network
Authors: V. Hautefeuille, C. Cuvelier, I. Sobhani, A. Grancher, H. Dupuis, L. Chaigneau, B. Verret, S. Watson, N. Penel, M. Toulmonde, W. Lahlou, L. Calavas, F. Ghiringhelli, M. Pracht, F. Mourthadhoi, M. Muller, L. Monceau-Baroux, D. Tougeron, O. Bouche, M. Brahmi
Journal: Annals of Oncology (2024)
1747P Changes in global health status (GHS) in patients with advanced soft tissue sarcoma (STS) treated with first line palliative chemotherapy: Primary outcomes from the HOLISTIC study
Authors: E. Roets, E. Younger, R.L. Jones, D. Den Hollander, L. Azarang, I. Desar, R. Young, A. Oosten, J.J. De Haan, H. Gelderblom, N. Steeghs, O. Husson, W.T.A. Van Der Graaf
Journal: Annals of Oncology (2024)
1745P How to optimize the response with trabectedin in soft tissue sarcomas? Data from a high-volume center
Authors: S. Diaz, L. Fernandez, G. Martínez Bernal, I.C. Carrasco Garcia, I. Rincon, J. Peinado, P. Sancho Marquez, A.L. Moreno Vega, M.J. Flor
Journal: Annals of Oncology (2024)
Lung Protective Mechanical Ventilation in Severe Acute Brain Injured Patients: A Multicenter, Randomized Clinical Trial (PROLABI)
Authors: Luciana Mascia, Vito Fanelli, Alice Mistretta, Matteo Filippini, Mattia Zanin, Maurizio Berardino, Anna Teresa Mazzeo, Anselmo Caricato, Massimo Antonelli, Francesco Della Corte, Francesca Grossi, Marina Munari, Massimiliano Caravello, Francesco Alessandri, Irene Cavalli, Mario Mezzapesa, Lucia Silvestri, Marilena Casartelli Liviero, Paolo Zanatta, Paolo Pelosi, Giuseppe Citerio, Claudia Filippini, Paola Rucci, Frank A. Rasulo, Tommaso Tonetti
Journal: American Journal of Respiratory and Critical Care Medicine (2024)

Lung protective strategies using low tidal volumes and moderate positive end expiratory pressures (PEEP) are considered best practice in critical care, but interventional trials have never been conducted in acutely brain-injured patients due to concerns about carbon dioxide control and effect of PEEP on cerebral hemodynamic.
Advances in reversible covalent kinase inhibitors
Authors: Zheng Zhao, Philip E. Bourne
Journal: Medicinal Research Reviews (2024)

Abstract Reversible covalent kinase inhibitors (RCKIs) are a class of novel kinase inhibitors attracting increasing attention because they simultaneously show the selectivity of covalent kinase inhibitors yet avoid permanent protein‐modification‐induced adverse effects. Over the last decade, RCKIs have been reported to target different kinases, including Atypical group of kinases. Currently, three RCKIs are undergoing clinical trials. Here, advances in RCKIs are reviewed to systematically summarize the characteristics of electrophilic groups, chemical scaffolds, nucleophilic residues, and binding modes. In so doing, we integrate key insights into privileged electrophiles, the distribution of nucleophiles, and hence effective design strategies for the development of RCKIs. Finally, we provide a further perspective on future design strategies for RCKIs, including those that target proteins other than kinases.
Current nanocomposite advances for biomedical and environmental application diversity
Authors: Narsimha Mamidi, Ramiro M. V. Delgadillo, Alan O. Sustaita, Karen Lozano, Murali M. Yallapu
Journal: Medicinal Research Reviews (2024)

Abstract Nanocomposite materials are emerging as key players in addressing critical challenges in healthcare, energy storage, and environmental remediation. These innovative systems hold great promise in engineering effective solutions for complex problems. Nanocomposites have demonstrated various advantages such as simplicity, versatility, lightweight, and potential cost‐effectiveness. By reinforcing synthetic and natural polymers with nanomaterials, a range of nanocomposites have exhibited unique physicochemical properties, biocompatibility, and biodegradability. Current research on nanocomposites has demonstrated promising clinical and translational applications. Over the past decade, the production of nanocomposites has emerged as a critical nano‐structuring methodology due to their adaptability and controllable surface structure. This comprehensive review article systematically addresses two principal domains. A comprehensive survey of metallic and nonmetallic nanomaterials (nanofillers), elucidating their efficacy as reinforcing agents in polymeric matrices. Emphasis is placed on the methodical design and engineering principles governing the development of functional nanocomposites. Additionally, the review provides an exhaustive examination of recent noteworthy advancements in industrial, environmental, biomedical, and clinical applications within the realms of nanocomposite materials. Finally, the review concludes by highlighting the ongoing challenges facing nanocomposites in a wide range of applications.
Management of atrial fibrillation in older adults
Authors: Anna L Parks, David S Frankel, Dae H Kim, Darae Ko, Daniel B Kramer, Melis Lydston, Margaret C Fang, Sachin J Shah
Journal: BMJ (2024)

Abstract Most people with atrial fibrillation are older adults, in whom atrial fibrillation co-occurs with other chronic conditions, polypharmacy, and geriatric syndromes such as frailty. Yet most randomized controlled trials and expert guidelines use an age agnostic approach. Given the heterogeneity of aging, these data may not be universally applicable across the spectrum of older adults. This review synthesizes the available evidence and applies rigorous principles of aging science. After contextualizing the burden of comorbidities and geriatric syndromes in people with atrial fibrillation, it applies an aging focused approach to the pillars of atrial fibrillation management, describing screening for atrial fibrillation, lifestyle interventions, symptoms and complications, rate and rhythm control, coexisting heart failure, anticoagulation therapy, and left atrial appendage occlusion devices. Throughout, a framework is suggested that prioritizes patients’ goals and applies existing evidence to all older adults, whether atrial fibrillation is their sole condition, one among many, or a bystander at the end of life.
Equipoise Lost? Trial Conduct Challenges in an Era of Breakthrough Therapies
Authors: Jaleh Fallah, Flora Mulkey, Mallorie H. Fiero, Haley Gittleman, Chi Song, Jeevan Puthiamadathil, Anup Amatya, Sundeep Agrawal, Paz Vellanki, Daniel L. Suzman, Harpreet Singh, Laleh Amiri-Kordestani, Pallavi Mishra-Kalyani, Richard Pazdur, Paul G. Kluetz
Journal: Journal of Clinical Oncology (2024)

FDA Oncology Center's @Falleh_Fallah and colleagues discuss loss of equipoise and other trial conduct challenges in an era of breakthrough therapies - via @JCO_ASCO.
Cumulative live birth rate of a blastocyst versus cleavage stage embryo transfer policy during in vitro fertilisation in women with a good prognosis: multicentre randomised controlled trial
Authors: Simone Cornelisse, Kathrin Fleischer, Lucette van der Westerlaken, Jan-Peter de Bruin, Carlijn Vergouw, Carolien Koks, Josien Derhaag, Jantien Visser, Jannie van Echten-Arends, Els Slappendel, Brigitte Arends, Moniek van der Zanden, Angelique van Dongen, Janneke Brink-van der Vlugt, Marcella de Hundt, Max Curfs, Harold Verhoeve, Maaike Traas-Hofmans, Yvonne Wurth, Petra Manger, Quirine Pieterse, Didi Braat, Madelon van Wely, Liliana Ramos, Sebastiaan Mastenbroek
Journal: BMJ (2024)

To evaluate whether embryo transfers at blastocyst stage improve the cumulative live birth rate after oocyte retrieval, including both fresh and frozen-thawed transfers, and whether the risk of obstetric and perinatal complications is increased compared with cleavage stage embryo transfers during in vitro fertilisation (IVF) treatment.
Copper homeostasis and cuproptosis in health and disease
Authors: Yunuo Yang, Jiaxuan Wu, Lisheng Wang, Guang Ji, Yanqi Dang
Journal: MedComm (2024)

Copper is a vital trace element in human physiology, essential for the synthesis of numerous crucial metabolic enzymes and facilitation of various biological processes. Regulation of copper levels within a narrow range is imperative for maintaining metabolic homeostasis. Numerous studies have demonstrated the significant roles of copper homeostasis and cuproptosis in health and disease pathogenesis. However, a comprehensive and up-to-date systematic review in this domain remains absent. This review aims to consolidate recent advancements in understanding the roles of cuproptosis and copper homeostasis in health and disease, focusing on the underlying mechanisms and potential therapeutic interventions. Dysregulation of copper homeostasis, manifesting as either copper excess or deficiency, is implicated in the etiology of various diseases. Cuproptosis, a recently identified form of cell death, is characterized by intracellular copper overload. This phenomenon mediates a diverse array of evolutionary processes in organisms, spanning from health to disease, and is implicated in genetic disorders, liver diseases, neurodegenerative disorders, and various cancers. This review provides a comprehensive summary of the pathogenic mechanisms underlying cuproptosis and copper homeostasis, along with associated targeted therapeutic agents. Furthermore, it explores future research directions with the potential to yield significant advancements in disease treatment, health management, and disease prevention.
High serum magnesium level is associated with increased mortality in patients with sepsis: an international, multicenter retrospective study
Authors: Le Li, Li Li, Qiuyue Zhao, Xiao Liu, Yaohui Liu, Kailin Guo, Dongsu Zhang, Chang Hu, Bo Hu
Journal: MedComm (2024)

Magnesium imbalances commonly exist in septic patients. However, the association of serum magnesium levels with mortality in septic patients remains uncertain. Herein, we elucidated the association between serum magnesium and all-cause mortality in septic patients from American and Chinese cohorts by analyzing data from 9099 patients in the Medical Information Mart for Intensive Care-IV (MIMIC-IV) database and 1727 patients from a university-affiliated hospital' intensive care unit in China. Patients in both cohorts were categorized into five groups based on serum magnesium quintiles from the MIMIC-IV dataset. Patients with higher serum magnesium levels exhibited an increased risk of 28-day mortality in both cohorts. The restricted cubic spline (RCS) curves revealed a progressively elevated risk of 28-day mortality with increasing serum magnesium in MIMIC-IV cohort, while a J-shaped correlation was observed in institutional cohort. Our findings have validated the association between high serum magnesium and high mortality in sepsis across different races and medical conditions. Serum magnesium levels might be useful in identifying septic patients at higher mortality risk.
How Racialized Approaches to Opioid Use Disorder and Opioid Misuse Management Hamper Pharmacoequity for Cancer Pain
Authors: Katie Fitzgerald Jones, Kevin T. Liou, Rebecca L. Ashare, Brooke Worster, Katherine A. Yeager, Jessica Merlin, Salimah H. Meghani
Journal: Journal of Clinical Oncology (2024)

@JCO_ASCO paper focuses on racialized approaches to OUD and opioid misuse as underappreciated drivers of disparities in cancer and recs a path forward.
Racial Differences in Breast Cancer Survival Between Black and White Women According to Tumor Subtype: A Systematic Review and Meta-Analysis
Authors: Juliana M. Torres, Michelle O. Sodipo, Margaret F. Hopkins, Paulette D. Chandler, Erica T. Warner
Journal: Journal of Clinical Oncology (2024)

PURPOSE Despite effective early-detection approaches and innovative treatments, Black women in the United States have higher breast cancer mortality rates compared with White women. The purpose of this systematic review and meta-analysis is to determine the extent of disparities in breast cancer survival between Black and White women according to tumor subtype. METHODS A comprehensive database search was performed for full-text, English-language articles published from January 1, 2000, to December 31, 2022. Included studies compared survival between Black and White female patients with breast cancer within subtypes defined by hormone receptor and human epidermal growth factor receptor 2 (HER2)/neu (HER2; now known as ERBB2) status. Random-effects models were used to combine study-specific results and generate pooled relative risks (RRs) and 95% CIs for breast cancer–specific or overall survival (OS). A protocol for this review was registered in PROSPERO (CRD42021268212). RESULTS Eighteen studies including 228,885 (34,262 Black; 182,466 White) patients with breast cancer were identified. Compared with White women, Black women had a higher risk of breast cancer death for all tumor subtypes. The summary risk of breast cancer death was 50% higher among hormone receptor-positive HER2-negative [HER2–] tumors (RR, 1.50 [95% CI, 1.30 to 1.72]), 34% higher for hormone receptor+/HER2+ (RR, 1.34 [95% CI, 1.10 to 1.64]), 20% higher for hormone receptor–negative (–)/HER2+ (RR, 1.29 [95% CI, 1.00 to 1.43]), and 17% higher among individuals with hormone receptor–/HER2– tumors (hazard ratio, 1.17; 95% CI, 1.10 to 1.25). Black women also had poorer OS than White women for all subtypes. CONCLUSION These results suggest there are both subtype-specific and subtype-independent mechanisms that contribute to disparities in breast cancer survival between Black and White women, which require multilevel interventions to address and achieve health equity.